よむ、つかう、まなぶ。
資料5-1 Ⅳ-137 テモゾロミド［801KB］ (41 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00047.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第69回 9／4）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-137
6149.
14. Federico SM, et al. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody
(hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with
Recurrent/Refractory Neuroblastoma. Clin Cancer Res. 2017, 23, 6441-6449.
15. Herd F, et al. A systematic review of re-induction chemotherapy for children with relapsed
high-risk neuroblastoma. Eur J Cancer. 2019, 111, 50-58.
16. Kushner BH, et al. irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J
Clin Oncol. 2006, 24, 5271-5276.
17. Kushner BH, et al. High-dose carboplatin-irinotecan-temozolomide: treatment option for
neuroblastoma resistant to topotecan. Pediatr Blood Cancer. 2011, 56, 403-408.
18. Modak S, et al. Combination of bevacizumab, irinotecan, and temozolomide for refractory or
relapsed neuroblastoma: Results of a phase II study. Pediatr Blood Cancer. 2017, 64(8).
19. Mody R, et al. irinotecan-temozolomide with temsirolimus or dinutuximab in children with
refractory or relapsed neuroblastoma (COGANGL1221): an open-label, randomised, phase 2
trial. Lancet Oncol. 2017, 18, 946-957.
20. Mody R, et al. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With
Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin
Oncol. 2020, 38, 2160-2169.
21. Moreno L, et al. Outcome of children with relapsed or refractory neuroblastoma: A metaanalysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer 2017, 64,
25–31.
22. Morgenstern DA, et al. Current and future strategies for relapsed neuroblastoma: challenges on
the road to precision therapy. J Pediatr Hematol Oncol. 2013, 35, 337-347.
23. National Cancer Institute-Physician Data Query (NCI-PDQ). Neuroblastoma Treatment
(PDQ®)–Health Professional Version.
https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq（アクセス
日：2026 年 1 月 7 日）
24. Nicholson HS, et al. Phase I Study of Temozolomide in Children and Adolescents with
Recurrent Solid Tumors: A Report from the Children's Cancer Group. J Clin Oncol. 1998, 16,
3037-3043.
25. Pizzo PA, et al. Principle and Practice of Pediatric Oncology (Seventh edition). Wolters
Kluwer. 2015.
26. Wagner LM, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients
with refractory solid tumors. Clin Cancer Res. 2004,10, 840-848.
27. Wagner LM, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed
high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin
Oncol. 2009, 27, 1290-1296.
38
6149.
14. Federico SM, et al. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody
(hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with
Recurrent/Refractory Neuroblastoma. Clin Cancer Res. 2017, 23, 6441-6449.
15. Herd F, et al. A systematic review of re-induction chemotherapy for children with relapsed
high-risk neuroblastoma. Eur J Cancer. 2019, 111, 50-58.
16. Kushner BH, et al. irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J
Clin Oncol. 2006, 24, 5271-5276.
17. Kushner BH, et al. High-dose carboplatin-irinotecan-temozolomide: treatment option for
neuroblastoma resistant to topotecan. Pediatr Blood Cancer. 2011, 56, 403-408.
18. Modak S, et al. Combination of bevacizumab, irinotecan, and temozolomide for refractory or
relapsed neuroblastoma: Results of a phase II study. Pediatr Blood Cancer. 2017, 64(8).
19. Mody R, et al. irinotecan-temozolomide with temsirolimus or dinutuximab in children with
refractory or relapsed neuroblastoma (COGANGL1221): an open-label, randomised, phase 2
trial. Lancet Oncol. 2017, 18, 946-957.
20. Mody R, et al. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With
Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin
Oncol. 2020, 38, 2160-2169.
21. Moreno L, et al. Outcome of children with relapsed or refractory neuroblastoma: A metaanalysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer 2017, 64,
25–31.
22. Morgenstern DA, et al. Current and future strategies for relapsed neuroblastoma: challenges on
the road to precision therapy. J Pediatr Hematol Oncol. 2013, 35, 337-347.
23. National Cancer Institute-Physician Data Query (NCI-PDQ). Neuroblastoma Treatment
(PDQ®)–Health Professional Version.
https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq（アクセス
日：2026 年 1 月 7 日）
24. Nicholson HS, et al. Phase I Study of Temozolomide in Children and Adolescents with
Recurrent Solid Tumors: A Report from the Children's Cancer Group. J Clin Oncol. 1998, 16,
3037-3043.
25. Pizzo PA, et al. Principle and Practice of Pediatric Oncology (Seventh edition). Wolters
Kluwer. 2015.
26. Wagner LM, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients
with refractory solid tumors. Clin Cancer Res. 2004,10, 840-848.
27. Wagner LM, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed
high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin
Oncol. 2009, 27, 1290-1296.
38